Psychiatry Research: Neuroimaging, 50:287-288
Elsevier

Reviewers for 1993

We wish to acknowledge the important assistance we have received from many scientists who, along with the Editorial Board, have evaluated manuscripts submitted for publication during 1993. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 49, Number 3, 1993).

Author Index for 1993

Abbruzzese, M. 50:45
Alliger, R. 50:283
Almas, M. 50:25
Andreasen, N.C. 50:283
Arndt, S. 50:283
Asarnow, R.F. 50:33
Bartzokis, G. 50:33
Bonfanti, A. 50:45, 50:89
Calabrese, G. 50:89
Calabrese, J. 50:77
Cardwell, D. 50:67
Chan, S. 50:143
Cohen, G. 50:283
Colombo, C. 50:45, 50:89
Coppola, R. 50:177
Cosyns, P. 50:77
Daniel, D.G. 50:177
DeCaria, C.M. 50:25, 50:143
Degreef, G. 50:193
DeLisi, L.E. 50:193
Devous, M.D., Sr. 50:233
Dierckx, R. 50:77
Dierks, T. 50:151
Eckardt, M.J. 50:101
Engel, R. 50:163
Ericson, K. 50:15
Eriksson, L. 50:15
Farde, L. 50:1
Fink, G. 50:93
Fredrikson, M. 50:15
Frölich, L. 50:151
Fukuda, H. 50:217
Fukui, S. 50:217
Fukuyama, H. 50:203
Giunta, R. 50:163
Granholm, E. 50:33
Grannemann, B.D. 50:233
Greitz, T. 50:15
Günther, W. 50:163
Gullion, C.M. 50:233
Haag, C. 50:163
Halldin, C. 50:1
Harris, G.J. 50:57
Heiss, W.-D. 50:93
Herholz, K. 50:93
Hilal, S. 50:143
Hindmarsh, T. 50:1
Hoff, A.L. 50:193
Hollander, E. 50:25, 50:143
Ihl, R. 50:151
Ingels, M. 50:77
Ishikura, S. 50:203
Itoh, T. 50:217
Iyo, M. 50:217
John, E.R. 50:25
Jonitz, L. 50:163
Joyce, E.M. 50:101
Karson, C.N. 50:67
Kato, T. 50:203
Klages, U. 50:163
Klein, D.F. 50:143
Koenig, T. 50:275
Komoroski, R.A. 50:67
Kushner, M. 50:193
Lehmann, D. 50:275
Levine, R.H. 50:25
Liebowitz, M. 50:25
Liebowitz, M.R. 50:143
Lim, K.O. 50:257
Litton, J.-E. 50:1
Livian, S. 50:45
Locatelli, M. 50:45
Maes, M. 50:77
Marder, S.R. 50:33
Marenco, S. 50:177
Mas, F. 50:25
Mathalon, D.H. 50:121, 50:257; 50:284
Maurer, K. 50:151
Meltzer, H.Y. 50:77
Michel, C.M. 50:275
Mielke, R. 50:93
Mohanakrishnan, P. 50:67

Morita, R. 50:203
Narita, M. 50:203
Neiman, J. 50:1
Newton, J.E.O. 50:67
Nishio, M. 50:217
Ohnishi, H. 50:203
Pauli, S. 50:1
Pearlson, G.D. 50:57
Pfefferbaum, A. 50:121, 50:257, 50:284
Prichep, L.S. 50:25
Rawles, J.M. 50:121, 50:284
Rio, D.E. 50:101
Ritter, D. 50:93
Rosenbloom, M.J. 50:257
Rush, A.J. 50:233
Ruttimann, U.E. 50:101
Satoh, K. 50:203
Satzger, W. 50:163
Scarone, S. 50:45, 50:89
Schotte, C. 50:77
Scotti, G. 50:45, 50:89
Sedvall, G. 50:1
Shear, P.K. 50:257
Shibasaki, M. 50:203
Sprigg, J.R. 50:67
Stein, D.J. 50:143
Steinberg, R. 50:163
Stone-Elander, S. 50:15
Sullivan, E.V. 50:121, 50:257, 50:284
Suzuki, K. 50:217
Suzuki, T. 50:203
Swayze, V.W. III 50:283
Takahashi, S. 50:203
Tateno, Y. 50:217
Trivedi, M.H. 50:233
Vandewoude, M. 50:77
Wackermann, J. 50:275
Weinberger, D.R. 50:177
Wik, G. 50:15
Yamasaki, T. 50:217
Zigun, J.R. 50:177

Psychiatry Research: Neuroimaging, 50:289-305
Elsevier

Subject Index for 1993

Affective disorder
aging, regional cerebral blood flow, 50:233
aging, single photon emission computed tomography, 50:233
aging, unipolar depression, 50:233
frontal lobes, regional cerebral blood flow, 50:77
frontal lobes, single photon emission computed tomography, 50:77
frontal lobes, unipolar depression, 50:77
regional cerebral blood flow, aging, 50:233
regional cerebral blood flow, frontal lobes, 50:77
regional cerebral blood flow, unipolar depression, 50:77, 50:233
single photon emission computed tomography, aging, 50:233
single photon emission computed tomography, frontal lobes, 50:77
single photon emission computed tomography, unipolar depression, 50:77, 50:233
unipolar depression, aging, 50:233
unipolar depression, frontal lobes, 50:77
unipolar depression, regional cerebral blood flow, 50:77, 50:233
unipolar depression, single photon emission computed tomography, 50:77, 50:233
Aging
affective disorder, regional cerebral blood flow, 50:233
affective disorder, single photon emission computed tomography, 50:233
alcohol dependence, cerebrospinal fluid volume, 50:257
alcohol dependence, computed tomography, 50:257
alcohol dependence, magnetic resonance imaging, 50:257
alcohol dependence, ventricle-brain ratio, 50:257
Alzheimer's disease, dipole analysis, 50:151
Alzheimer's disease, electroencephalography, 50:151, 50:163
Alzheimer's disease, motor performance, 50:163
Alzheimer's disease, music perception, 50:163
Alzheimer's disease, spectral analysis, 50:151
Alzheimer's disease, temporal lobes, 50:163
basal ganglia, frontal lobes, 50:93
basal ganglia, myotonic dystrophy, 50:93
basal ganglia, positron emission tomography, 50:93
cerebrospinal fluid volume, alcohol dependence, 50:257
Aging continued
cerebrospinal fluid volume, computed tomography, 50:257
cerebrospinal fluid volume, magnetic resonance imaging, 50:257
cerebrospinal fluid volume, ventricle-brain ratio, 50:257
computed tomography, alcohol dependence, 50:257
computed tomography, cerebrospinal fluid volume, 50:257
computed tomography, magnetic resonance imaging, 50:257
computed tomography, ventricle-brain ratio, 50:257
dipole analysis, Alzheimer's disease, 50:151
dipole analysis, electroencephalography, 50:151
dipole analysis, spectral analysis, 50:151
electroencephalography, Alzheimer's disease, 50:151, 163
electroencephalography, dipole analysis, 50:151
electroencephalography, motor performance, 50:163
electroencephalography, music perception, 50:163
electroencephalography, spectral analysis, 50:151
electroencephalography, temporal lobes, 50:163
frontal lobes, basal ganglia, 50:93
frontal lobes, myotonic dystrophy, 50:93
frontal lobes, positron emission tomography, 50:93
magnetic resonance imaging, alcohol dependence, 50:257
magnetic resonance imaging, cerebrospinal fluid volume, 50:257
magnetic resonance imaging, computed tomography, 50:257
magnetic resonance imaging, ventricle-brain ratio, 50:257
motor performance, Alzheimer's disease, 50:163
motor performance, electroencephalography, 50:163
motor performance, temporal lobes, 50:163
music perception, Alzheimer's disease, 50:163
music perception, electroencephalography, 50:163
myotonic dystrophy, basal ganglia, 50:93
myotonic dystrophy, frontal lobes, 50:93
myotonic dystrophy, positron emission tomography, 50:93

Aging continued
positron emission tomography, basal ganglia, 50:93
positron emission tomography, frontal lobes, 50:93
positron emission tomography, myotonic dystrophy, 50:93
regional cerebral blood flow, affective disorder, 50:233
regional cerebral blood flow, unipolar depression, 50:233
single photon emission computed tomography, affective disorder, 50:233
single photon emission computed tomography, unipolar depression, 50:233
spectral analysis, Alzheimer's disease, 50:151
spectral analysis, dipole analysis, 50:151
spectral analysis, electroencephalography, 50:151
temporal lobes, Alzheimer's disease, 50:163
temporal lobes, electroencephalography, 50:163
temporal lobes, motor performance, 50:163
unipolar depression, regional cerebral blood flow, 50:233
unipolar depression, single photon emission computed tomography, 50:233
ventricle-brain ratio, alcohol dependence, 50:257
ventricle-brain ratio, cerebrospinal fluid volume, 50:257
ventricle-brain ratio, computed tomography, 50:257
ventricle-brain ratio, magnetic resonance imaging, 50:257
Alcohol dependence
aging, cerebrospinal fluid volume, 50:257
aging, computed tomography, 50:257
aging, magnetic resonance imaging, 50:257
aging, ventricle-brain ratio, 50:257
benzodiazepine receptor, flumazenil, 50:1
benzodiazepine receptor, magnetic resonance imaging, 50:1
benzodiazepine receptor, positron emission tomography, 50:1
cerebrospinal fluid volume, aging, 50:257
cerebrospinal fluid volume, computed tomography, 50:257
cerebrospinal fluid volume, magnetic resonance imaging, 50:257
cerebrospinal fluid volume, ventricle-brain ratio, 50:257
computed tomography, aging, 50:257
computed tomography, cerebrospinal fluid volume, 50:257
Alcohol dependence continued
computed tomography, image segmentation, 50:101
computed tomography, Korsakoff syndrome, 50:101
computed tomography, magnetic resonance imaging, 50:257
computed tomography, thresholding methods, 50:101
computed tomography, ventricle-brain ratio, 50:257
flumazenil, benzodiazepine receptor, 50:1
flumazenil, magnetic resonance imaging, 50:1
flumazenil, positron emission tomography, 50:1
image segmentation, computed tomography, 50:101
image segmentation, Korsakoff syndrome, 50:101
image segmentation, thresholding methods, 50:101
Korsakoff syndrome, computed tomography, 50:101
Korsakoff syndrome, image segmentation, 50:101
Korsakoff syndrome, thresholding methods, 50:101
magnetic resonance imaging, aging, 50:257
magnetic resonance imaging, benzodiazepine receptor, 50:1
magnetic resonance imaging, cerebrospinal fluid volume, 50:257
magnetic resonance imaging, computed tomography, 50:257
magnetic resonance imaging, flumazenil, 50:1
magnetic resonance imaging, positron emission tomography, 50:1
magnetic resonance imaging, ventricle-brain ratio, 50:1, 50:257
positron emission tomography, benzodiazepine receptor, 50:1
positron emission tomography, flumazenil, 50:1
positron emission tomography, magnetic resonance imaging, 50:1
thresholding methods, computed tomography, 50:101
thresholding methods, image segmentation, 50:101
thresholding methods, Korsakoff syndrome, 50:101
ventricle-brain ratio, aging, 50:257
ventricle-brain ratio, cerebrospinal fluid volume, 50:257
ventricle-brain ratio, computed tomography, 50:257
ventricle-brain ratio, magnetic resonance imaging, 50:1, 50:257
Alzheimer's disease
aging, dipole analysis, 50:151
aging, electroencephalography, 50:151, 50:163

Alzheimer's disease continued
aging, motor performance, 50:163
aging, music perception, 50:163
aging, spectral analysis, 50:151
aging, temporal lobes, 50:163
dipole analysis, aging, 50:151
dipole analysis, electroencephalography, 50:151
dipole analysis, spectral analysis, 50:151
electroencephalography, aging, 50:151, 163
electroencephalography, dipole analysis, 50:151
electroencephalography, motor performance, 50:163
electroencephalography, music perception, 50:163
electroencephalography, spectral analysis, 50:151
electroencephalography, temporal lobes, 50:163
motor performance, aging, 50:163
motor performance, electroencephalography, 50:163
motor performance, temporal lobes, 50:163
music perception, aging, 50:163
music perception, electroencephalography, 50:163
spectral analysis, aging, 50:151
spectral analysis, dipole analysis, 50:151
spectral analysis, electroencephalography, 50:151
temporal lobes, aging, 50:163
temporal lobes, electroencephalography, 50:163
temporal lobes, motor performance, 50:163
Anxiety
phobia, positron emission tomography, 50:15
phobia, regional cerebral blood flow, 50:15
positron emission tomography, phobia, 50:15
regional cerebral blood flow, phobia, 50:15
Basal ganglia
aging, frontal lobes, 50:93
aging, myotonic dystrophy, 50:93
aging, positron emission tomography, 50:93
caudate nucleus, magnetic resonance imaging, 50:89
caudate nucleus, obsessive-compulsive disorder, 50:89
computed tomography, neurological soft signs, 50:143
computed tomography, obsessive-compulsive disorder, 50:143 computed tomography, ventricle-brain ratio, 50:143
dopamine D_2 receptors, methamphetamine psychosis, 50:217
Basal ganglia continued
dopamine D_2 receptors, methylspiperone, 50:217
dopamine D_2 receptors, positron emission tomography, 50:217
dopamine D_2 receptors, serotonin S_2 receptors, 50:217
frontal lobes, aging, 50:93
frontal lobes, myotonic dystrophy, 50:93
frontal lobes, positron emission tomography, 50:93
magnetic resonance imaging, caudate nucleus, 50:89
magnetic resonance imaging, motor learning, 50:33
magnetic resonance imaging, obsessive-compulsive disorder, 50:89
magnetic resonance imaging, schizophrenia, 50:33
magnetic resonance imaging, tardive dyskinesia, 50:33
methamphetamine psychosis, dopamine D_2 receptors, 50:217
methamphetamine psychosis, methylspiperone, 50:217
methamphetamine psychosis, positron emission tomography, 50:217
methamphetamine psychosis, serotonin S_2 receptors, 50:217
methylspiperone, dopamine D_2 receptors, 50:217
methylspiperone, methamphetamine psychosis, 50:217
methylspiperone, positron emission tomography, 50:217
methylspiperone, serotonin S_2 receptors, 50:217
motor learning, magnetic resonance imaging, 50:33
motor learning, schizophrenia, 50:33
motor learning, tardive dyskinesia, 50:33
myotonic dystrophy, aging, 50:93
myotonic dystrophy, frontal lobes, 50:93
myotonic dystrophy, positron emission tomography, 50:93
neurological soft signs, computed tomography, 50:143
neurological soft signs, obsessive-compulsive disorder, 50:143
neurological soft signs, ventricle-brain ratio, 50:143
obsessive-compulsive disorder, caudate nucleus, 50:89
obsessive-compulsive disorder, computed tomography, 50:143

Basal ganglia continued
obsessive-compulsive disorder, magnetic resonance imaging, 50:89
obsessive-compulsive disorder, neurological soft signs, 50:143
obsessive-compulsive disorder, ventricle-brain ratio, 50:143
positron emission tomography, aging, 50:93
positron emission tomography, dopamine D_2 receptors, 50:217
positron emission tomography, frontal lobes, 50:93
positron emission tomography, methamphetamine psychosis, 50:217
positron emission tomography, methylspiperone, 50:217
positron emission tomography, myotonic dystrophy, 50:93
positron emission tomography, serotonin S_2 receptors, 50:217
schizophrenia, magnetic resonance imaging, 50:33
schizophrenia, motor learning, 50:33
schizophrenia, tardive dyskinesia, 50:33
serotonin S_2 receptors, dopamine D_2 receptors, 50:217
serotonin S_2 receptors, methamphetamine psychosis, 50:217
serotonin S_2 receptors, methylspiperone, 50:217
serotonin S_2 receptors, positron emission tomography, 50:217
tardive dyskinesia, magnetic resonance imaging, 50:33
tardive dyskinesia, motor learning, 50:33
tardive dyskinesia, schizophrenia, 50:33
ventricle-brain ratio, computed tomography, 50:143
ventricle-brain ratio, obsessive-compulsive disorder, 50:143
ventricle-brain ratio, neurological soft signs, 50:143
Benzodiazepines
alcohol dependence, flumazenil, 50:1
alcohol dependence, magnetic resonance imaging, 50:1
alcohol dependence, positron emission tomography, 50:1
flumazenil, alcohol dependence, 50:1
flumazenil, magnetic resonance imaging, 50:1
flumazenil, positron emission tomography, 50:1
magnetic resonance imaging, alcohol dependence, 50:1
magnetic resonance imaging, flumazenil, 50:1
Benzodiazepines continued
magnetic resonance imaging, positron emission tomography, 50:1
positron emission tomography, alcohol dependence, 50:1
positron emission tomography, flumazenil, 50:1
positron emission tomography, magnetic resonance imaging, 50:1
Cavum septum pellucidum
development, magnetic resonance imaging, 50:193
development, schizophrenia, 50:193
magnetic resonance imaging, development, 50:193
magnetic resonance imaging, schizophrenia, 50:193
schizophrenia, development, 50:193
schizophrenia, magnetic resonance imaging, 50:193
Cerebral blood flow. See Regional cerebral imaging, blood flow.
Cerebrospinal fluid volume
aging, alcohol dependence, 50:257
aging, computed tomography, 50:257
aging, magnetic resonance imaging, 50:257
aging, ventricle-brain ratio, 50:257
alcohol dependence, aging, 50:257
alcohol dependence, computed tomography, 50:257
alcohol dependence, magnetic resonance imaging, 50:257
alcohol dependence, ventricle-brain ratio, 50:257
computed tomography, aging, 50:257
computed tomography, alcohol dependence, 50:257
computed tomography, magnetic resonance 50:257
computed tomography, ventricle-brain ratio, 50:257
magnetic resonance imaging, aging, 50:257
magnetic resonance imaging, alcohol dependence, 50:257
magnetic resonance imaging, computed tomography, 50:257
magnetic resonance imaging, ventricle-brain ratio, 50:257
ventricle-brain ratio, aging, 50:257
ventricle-brain ratio, alcohol dependence, 50:257
ventricle-brain ratio, computed tomography, 50:257
ventricle-brain ratio, magnetic resonance imaging, 50:257

Clomipramine
clinical response prediction, electroencephalography, 50:25
electroencephalography, clinical response prediction, 50:25
Cognition
electroencephalography, nootropic, 50:275
electroencephalography, piracetam, 50:275
electroencephalography, topographic analysis, 50:275
nootropic, electroencephalography, 50:275
nootropic, piracetam, 50:275
nootropic, topographic analysis, 50:275
piracetam, electroencephalography, 50:275
piracetam, nootropic, 50:275
piracetam, topographic analysis, 50:275
topographic analysis, electroencephalography, 50:275
topographic analysis, nootropic, 50:275
topographic analysis, piracetam, 50:275
Computed tomography
aging, alcohol dependence, 50:257
aging, cerebrospinal fluid volume, 50:257
aging, magnetic resonance imaging, 50:257
aging, ventricle-brain ratio, 50:257
alcohol dependence, aging, 50:257
alcohol dependence, cerebrospinal fluid volume, 50:257
alcohol dependence, image segmentation, 50:101
alcohol dependence, Korsakoff syndrome, 50:101
alcohol dependence, magnetic resonance imaging, 50:257
alcohol dependence, thresholding methods, 50:101
alcohol dependence, ventricle-brain ratio, 50:257
basal ganglia, neurological soft signs, 50:143
basal ganglia, obsessive-compulsive disorder, 50:143
basal ganglia, ventricle-brain ratio, 50:143
cerebrospinal fluid volume, aging, 50:257
cerebrospinal fluid volume, alcohol dependence, 50:257
cerebrospinal fluid volume, magnetic resonance imaging, 50:257
cerebrospinal fluid volume, ventricle-brain ratio, 50:257
head size, magnetic resonance imaging, 50:121
head size, ventricle-brain ratio, 50:121
image segmentation, alcohol dependence, 50:101
image segmentation, Korsakoff syndrome, 50:101
Computed tomography continued
image segmentation, thresholding methods, 50:101
Korsakoff syndrome, alcohol dependence, 50:101
Korsakoff syndrome, image segmentation, 50:101
Korsakoff syndrome, thresholding methods, 50:101
magnetic resonance imaging, aging, 50:257
magnetic resonance imaging, alcohol dependence, 50:257
magnetic resonance imaging, cerebrospinal fluid volume, 50:257
magnetic resonance imaging, head size, 50:121
magnetic resonance imaging, ventricle-brain ratio, 50:121, 50:257
neurological soft signs, basal ganglia, 50:143
neurological soft signs, obsessive-compulsive disorder, 50:143
neurological soft signs, ventricle-brain ratio, 50:143
obsessive-compulsive disorder, basal ganglia, 50:143
obsessive-compulsive disorder, neurological soft signs, 50:143
obsessive-compulsive disorder, ventricle-brain ratio, 50:143
thresholding methods, alcohol dependence, 50:101
thresholding methods, image segmentation, 50:101
thresholding methods, Korsakoff syndrome, 50:101
ventricle-brain ratio, aging, 50:257
ventricle-brain ratio, alcohol dependence, 50:257
ventricle-brain ratio, basal ganglia, 50:143
ventricle-brain ratio, cerebrospinal fluid volume, 50:257
ventricle-brain ratio, head size, 50:121
ventricle-brain ratio, magnetic resonance imaging, 50:121, 50:257
ventricle-brain ratio, neurological soft signs, 50:143
ventricle-brain ratio, obsessive-compulsive disorder, 50:143
Dementia. See Alzheimer's disease.
Depression. See Affective disorder.
Development
cavum septum pellucidum, magnetic resonance imaging, 50:193
cavum septum pellucidum, schizophrenia, 50:193

Development continued
magnetic resonance imaging, cavum septum pellucidum, 50:193
magnetic resonance imaging, schizophrenia, 50:193
schizophrenia, cavum septum pellucidum, 50:193
schizophrenia, magnetic resonance imaging, 50:193
Dopamine
basal ganglia, methamphetamine psychosis, 50:217
basal ganglia, methylspiperone, 50:217
basal ganglia, positron emission tomography, 50:217
basal ganglia, serotonin S_2 receptors, 50:217
methamphetamine psychosis, basal ganglia, 50:217
methamphetamine psychosis, methylspiperone, 50:217
methamphetamine psychosis, positron emission tomography, 50:217
methamphetamine psychosis, serotonin S_2 receptors, 50:217
methylspiperone, basal ganglia, 50:217
methylspiperone, methamphetamine psychosis, 50:217
methylspiperone, positron emission tomography, 50:217
methylspiperone, serotonin S_2 receptors, 50:217
positron emission tomography, basal ganglia, 50:217
positron emission tomography, methamphetamine psychosis, 50:217
positron emission tomography, methylspiperone, 50:217
positron emission tomography, serotonin S_2 receptors, 50:217
serotonin S_2 receptors, basal ganglia, 50:217
serotonin S_2 receptors, methamphetamine psychosis, 50:217
serotonin S_2 receptors, methylspiperone, 50:217
serotonin S2 receptors, positron emission tomography, 50:217
Electroencephalography
aging, Alzheimer's disease, 50:151, 50:163
aging, dipole analysis, 50:151
aging, motor performance, 50:163
aging, music perception, 50:163
aging, spectral analysis, 50:151
aging, temporal lobes, 50:163
Alzheimer's disease, aging, 50:151, 50:163
Alzheimer's disease, dipole analysis, 50:151
Electroencephalography continued
Alzheimer's disease, motor performance, 50:163
Alzheimer's disease, music perception, 50:163
Alzheimer's disease, spectral analysis, 50:151
Alzheimer's disease, temporal lobes, 50:163
clinical response prediction, fluoxetine, 50:25
clinical response prediction, obsessive-compulsive disorder, 50:25
clinical response prediction, serotonin reuptake inhibitors, 50:25
cognition, nootropic, 50:275
cognition, piracetam, 50:275
cognition, topographic analysis, 50:275
dipole analysis, aging, 50:151
dipole analysis, Alzheimer's disease, 50:151
dipole analysis, spectral analysis, 50:151
fluoxetine, clinical response prediction, 50:25
fluoxetine, obsessive-compulsive disorder, 50:25
motor performance, aging, 50:163
motor performance, Alzheimer's disease, 50:163
motor performance, temporal lobes, 50:163
music perception, aging, 50:163
music perception, Alzheimer's disease, 50:163
nootropic, cognition, 50:275
nootropic, topographic analysis, 50:275
obsessive-compulsive disorder, clinical response prediction, 50:25
obsessive-compulsive disorder, fluoxetine, 50:25
obsessive-compulsive disorder, serotonin reuptake inhibitors, 50:25
piracetam, cognition, 50:275
piracetam, topographic analysis, 50:275
serotonin reuptake inhibitors, clinical response prediction, 50:25
serotonin reuptake inhibitors, obsessive-compulsive disorder, 50:25
space-oriented segmentation, topographic analysis, 50:275
spectral analysis, aging, 50:151
spectral analysis, Alzheimer's disease, 50:151
spectral analysis, dipole analysis, 50:151
temporal lobes, aging, 50:163
temporal lobes, Alzheimer's disease, 50:163
temporal lobes, motor performance, 50:163
topographic analysis, cognition, 50:275
topographic analysis, nootropic, 50:275
topographic analysis, piracetam, 50:275
topographic analysis, space-oriented segmentation, 50:275

Flumazenil
alcohol dependence, benzodiazepine receptor, 50:1
alcohol dependence, magnetic resonance imaging, 50:1
alcohol dependence, positron emission tomography, 50:1
benzodiazepine receptor, alcohol dependence, 50:1
benzodiazepine receptor, magnetic resonance imaging, 50:1
benzodiazepine receptor, positron emission tomography, 50:1
magnetic resonance imaging, alcohol dependence, 50:1
magnetic resonance imaging, benzodiazepine receptor, 50:1
magnetic resonance imaging, positron emission tomography, 50:1
positron emission tomography, alcohol dependence, 50:1
positron emission tomography, benzodiazepine receptor, 50:1
positron emission tomography, magnetic resonance imaging, 50:1
Fluoxetine
clinical response prediction, electroencephalography, 50:25
clinical response prediction, obsessive-compulsive disorder, 50:25
electroencephalography, clinical response prediction, 50:25
electroencephalography, obsessive-compulsive disorder, 50:25
obsessive-compulsive disorder, clinical response prediction, 50:25
obsessive-compulsive disorder, electroencephalography, 50:25
Fluvoxamine
clinical response prediction, electroencephalography, 50:25
electroencephalography, clinical response prediction, 50:25
Frontal lobes
affective disorder, regional cerebral blood flow, 50:77
affective disorder, single photon emission computed tomography, 50:77
aging, basal ganglia, 50:93
aging, myotonic dystrophy, 50:93
aging, positron emission tomography, 50:93
basal ganglia, aging, 50:93
basal ganglia, myotonic dystrophy, 50:93
basal ganglia, positron emission tomography, 50:93
Frontal lobes continued
catatonia, iodoamphetamine, 50:203
catatonia, parietal lobes, 50:203
catatonia, regional cerebral blood flow, 50:203
catatonia, schizophrenia, 50:203
catatonia, single photon emission computed tomography, 50:203
iodoamphetamine, catatonia, 50:203
iodoamphetamine, parietal lobes, 50:203
iodoamphetamine, regional cerebral blood flow, 50:203
iodoamphetamine, schizophrenia, 50:203
iodoamphetamine, single photon emission computed tomography, 50:203
myotonic dystrophy, aging, 50:93
myotonic dystrophy, basal ganglia, 50:93
myotonic dystrophy, positron emission tomography, 50:93
parietal lobes, catatonia, 50:203
parietal lobes, iodoamphetamine, 50:203
parietal lobes, regional cerebral blood flow, 50:203
parietal lobes, schizophrenia, 50:203
parietal lobes, single photon emission computed tomography, 50:203
positron emission tomography, aging, 50:93
positron emission tomography, basal ganglia, 50:93
positron emission tomography, myotonic dystrophy, 50:93
regional cerebral blood flow, affective disorder, 50:77
regional cerebral blood flow, catatonia, 50:203
regional cerebral blood flow, iodoamphetamine, 50:203
regional cerebral blood flow, parietal lobes, 50:203
regional cerebral blood flow, schizophrenia, 50:203
regional cerebral blood flow, single photon emission computed tomography, 50:77
regional cerebral blood flow, single photon emission computed tomography, 50:177
regional cerebral blood flow, single photon emission computed tomography, 50:203
regional cerebral blood flow, task difficulty, 50:177
regional cerebral blood flow, unipolar depression, 50:77
regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
schizophrenia, catatonia, 50:203
schizophrenia, iodoamphetamine, 50:203

Frontal lobes continued
schizophrenia, parietal lobes, 50:203
schizophrenia, regional cerebral blood flow, 50:203
schizophrenia, single photon emission computed tomography, 50:203
single photon emission computed tomography, affective disorder, 50:77
single photon emission computed tomography, catatonia, 50:203
single photon emission computed tomography, iodoamphetamine, 50:203
single photon emission computed tomography, parietal lobes, 50:203
single photon emission computed tomography, schizophrenia, 50:203
single photon emission computed tomography, task difficulty, 50:177
single photon emission computed tomography, unipolar depression, 50:77
single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
task difficulty, regional cerebral blood flow, 50:177
task difficulty, single photon emission computed tomography, 50:177
task difficulty, Wisconsin Card Sorting Test, 50:177
unipolar depression, regional cerebral blood flow, 50:77
unipolar depression, single photon emission computed tomography, 50:77
Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
Wisconsin Card Sorting Test, task difficulty, 50:177
Image reconstruction
magnetic resonance imaging, region of interest, 50:57
magnetic resonance imaging, single photon emission computed tomography, 50:57
region of interest, magnetic resonance imaging, 50:57
region of interest, single photon emission computed tomography, 50:57
single photon emission computed tomography, magnetic resonance imaging, 50:57
single photon emission computed tomography, region of interest, 50:57
Image segmentation
alcohol dependence, computed tomography, 50:101
Image segmentation continued
alcohol dependence, Korsakoff syndrome, 50:101
alcohol dependence, thresholding methods, 50:101
computed tomography, alcohol dependence, 50:101
computed tomography, Korsakoff syndrome, 50:101
computed tomography, thresholding methods, 50:101
Korsakoff syndrome, alcohol dependence, 50:101
Korsakoff syndrome, computed tomography, 50:101
Korsakoff syndrome, thresholding methods, 50:101
thresholding methods, alcohol dependence, 50:101
thresholding methods, computed tomography, 50:101
thresholding methods, Korsakoff syndrome, 50:101
Iodoamphetamine
catatonia, frontal lobes, 50:203
catatonia, parietal lobes, 50:203
catatonia, regional cerebral blood flow, 50:203
catatonia, schizophrenia, 50:203
catatonia, single photon emission computed tomography, 50:203
frontal lobes, catatonia, 50:203
frontal lobes, parietal lobes, 50:203
frontal lobes, regional cerebral blood flow, 50:203
frontal lobes, schizophrenia, 50:203
frontal lobes, single photon emission computed tomography, 50:203
parietal lobes, catatonia, 50:203
parietal lobes, frontal lobes, 50:203
parietal lobes, regional cerebral blood flow, 50:203
parietal lobes, schizophrenia, 50:203
parietal lobes, single photon emission computed tomography, 50:203
regional cerebral blood flow, catatonia, 50:203
regional cerebral blood flow, frontal lobes, 50:203
regional cerebral blood flow, parietal lobes, 50:203
regional cerebral blood flow, schizophrenia, 50:203
schizophrenia, catatonia, 50:203
schizophrenia, frontal lobes, 50:203

Iodoamphetamine continued
schizophrenia, parietal lobes, 50:203
schizophrenia, regional cerebral blood flow, 50:203
schizophrenia, single photon emission computed tomography, 50:203
single photon emission computed tomography, catatonia, 50:203
single photon emission computed tomography, frontal lobes, 50:203
single photon emission computed tomography, parietal lobes, 50:203
single photon emission computed tomography, schizophrenia, 50:203
Korsakoff syndrome
alcohol dependence, computed tomography, 50:101
alcohol dependence, image segmentation, 50:101
alcohol dependence, thresholding methods, 50:101
computed tomography, alcohol dependence, 50:101
computed tomography, image segmentation, 50:101
computed tomography, thresholding methods, 50:101
image segmentation, alcohol dependence, 50:101
image segmentation, computed tomography, 50:101
image segmentation, thresholding methods, 50:101
thresholding methods, alcohol dependence, 50:101
thresholding methods, computed tomography, 50:101
thresholding methods, image segmentation, 50:101
Lithium
magnetic resonance spectroscopy, pharmacokinetics, 50:67
pharmacokinetics, magnetic resonance spectroscopy, 50:67
Magnetic resonance imaging
aging, alcohol dependence, 50:257
aging, cerebrospinal fluid volume, 50:257
aging, computed tomography, 50:257
aging, ventricle-brain ratio, 50:257
alcohol dependence, aging, 50:257
alcohol dependence, benzodiazepine receptor, 50:1
alcohol dependence, cerebrospinal fluid volume, 50:257
Magnetic resonance imaging continued
alcohol dependence, computed tomography, 50:257
alcohol dependence, flumazenil, 50:1
alcohol dependence, positron emission tomography, 50:1
alcohol dependence, ventricle-brain ratio, 50:1, 50:257
basal ganglia, motor learning, 50:33
basal ganglia, obsessive-compulsive disorder, 50:89
basal ganglia, schizophrenia, 50:33
basal ganglia, tardive dyskinesia, 50:33
benzodiazepine receptor, alcohol dependence, 50:1
benzodiazepine receptor, flumazenil, 50:1
benzodiazepine receptor, positron emission tomography, 50:1
caudate nucleus, obsessive-compulsive disorder, 50:89
cavum septum pellucidum, development, 50:193
cavum septum pellucidum, schizophrenia, 50:193
cerebrospinal fluid volume, aging, 50:257
cerebrospinal fluid volume, alcohol dependence, 50:257
cerebrospinal fluid volume, computed tomography, 50:257
cerebrospinal fluid volume, ventricle-brain ratio, 50:257
computed tomography, aging, 50:257
computed tomography, alcohol dependence, 50:257
computed tomography, cerebrospinal fluid volume, 50:257
computed tomography, head size, 50:121
computed tomography, ventricle-brain ratio, 50:121, 50:257
development, cavum septum pellucidum, 50:193
development, schizophrenia, 50:193
flumazenil, alcohol dependence, 50:1
flumazenil, benzodiazepine receptor, 50:1
flumazenil, positron emission tomography, 50:1
head size, computed tomography, 50:121
head size correction, reliability, 50:203
head size, schizophrenia, 50:121
head size, ventricle-brain ratio, 50:121
image registration, region of interest, 50:57
image registration, single photon emission computed tomography, 50:57
memory, schizophrenia, 50:45
memory, temporal lobe area, 50:45

Magnetic resonance imaging continued
motor learning, basal ganglia, 50:33
motor learning, schizophrenia, 50:33
motor learning, tardive dyskinesia, 50:33
obsessive-compulsive disorder, basal ganglia, 50:89
obsessive-compulsive disorder, caudate nucleus, 50:89
positron emission tomography, alcohol dependence, 50:1
positron emission tomography, benzodiazepine receptor, 50:1
positron emission tomography, flumazenil, 50:1
region of interest, image registration, 50:57
region of interest, single photon emission computed tomography, 50:57
reliability, head size correction, 50:203
schizophrenia, basal ganglia, 50:33
schizophrenia, cavum septum pellucidum, 50:193
schizophrenia, development, 50:193
schizophrenia, head size, 50:121
schizophrenia, memory, 50:45
schizophrenia, motor learning, 50:33
schizophrenia, tardive dyskinesia, 50:33
schizophrenia, temporal lobe area, 50:45
single photon emission computed tomography, image registration, 50:57
single photon emission computed tomography, region of interest, 50:57
tardive dyskinesia, basal ganglia, 50:33
tardive dyskinesia, motor learning, 50:33
tardive dyskinesia, schizophrenia, 50:33
temporal lobe area, memory, 50:45
temporal lobe area, schizophrenia, 50:45
ventricle-brain ratio, aging, 50:257
ventricle-brain ratio, alcohol dependence, 50:1, 50:257
ventricle-brain ratio, cerebrospinal fluid volume, 50:257
ventricle-brain ratio, computed tomography, 50:121, 50:257
ventricle-brain ratio, head size, 50:121
Magnetic resonance spectroscopy
lithium, pharmacokinetics, 50:67
pharmacokinetics, lithium, 50:67
Memory
magnetic resonance imaging, schizophrenia, 50:45
magnetic resonance imaging, temporal lobe area, 50:45
schizophrenia, magnetic resonance imaging, 50:45
schizophrenia, temporal lobe area, 50:45
Magnetic resonance spectroscopy continued
temporal lobe area, magnetic resonance imaging, 50:45
temporal lobe area, schizophrenia, 50:45
Methamphetamine
basal ganglia, dopamine D_2 receptors, 50:217
basal ganglia, methylspiperone, 50:217
basal ganglia, positron emission tomography, 50:217
basal ganglia, serotonin S_2 receptors, 50:217
dopamine D_2 receptors, basal ganglia, 50:217
dopamine D_2 receptors, methylspiperone, 50:217
dopamine D_2 receptors, positron emission tomography, 50:217
dopamine D_2 receptors, serotonin S_2 receptors, 50:217
methylspiperone, basal ganglia, 50:217
methylspiperone, dopamine D_2 receptors, 50:217
methylspiperone, positron emission tomography, 50:217
methylspiperone, serotonin S_2 receptors, 50:217
positron emission tomography, basal ganglia, 50:217
positron emission tomography, dopamine D_2 receptors, 50:217
positron emission tomography, methylspiperone, 50:217
positron emission tomography, serotonin S_2 receptors, 50:217
serotonin S_2 receptors, basal ganglia, 50:217
serotonin S_2 receptors, dopamine D_2 receptors, 50:217
serotonin S_2 receptors, methylspiperone, 50:217
serotonin S_2 receptors, positron emission tomography, 50:217
Methylspiperone
basal ganglia, dopamine D_2 receptors, 50:217
basal ganglia, methamphetamine psychosis, 50:217
basal ganglia, positron emission tomography, 50:217
basal ganglia, serotonin S_2 receptors, 50:217
dopamine D_2 receptors, basal ganglia, 50:217
dopamine D_2 receptors, methamphetamine psychosis, 50:217
dopamine D_2 receptors, positron emission tomography, 50:217
dopamine D_2 receptors, serotonin S_2 receptors, 50:217
methamphetamine psychosis, basal ganglia, 50:217
methamphetamine psychosis, dopamine D_2 receptors, 50:217

Methylspiperone continued
methamphetamine psychosis, positron emission tomography, 50:217
methamphetamine psychosis, serotonin S_2 receptors, 50:217
positron emission tomography, basal ganglia, 50:217
positron emission tomography, dopamine D_2 receptors, 50:217
positron emission tomography, methamphetamine psychosis, 50:217
positron emission tomography, serotonin S_2 receptors, 50:217
serotonin S_2 receptors, basal ganglia, 50:217
serotonin S_2 receptors, dopamine D_2 receptors, 50:217
serotonin S_2 receptors, methamphetamine psychosis, 50:217
serotonin S_2 receptors, positron emission tomography, 50:217
Motor performance
aging, Alzheimer's disease, 50:163
aging, electroencephalography, 50:163
aging, temporal lobes, 50:163
Alzheimer's disease, aging, 50:163
Alzheimer's disease, electroencephalography, 50:163
Alzheimer's disease, temporal lobes, 50:163
electroencephalography, aging, 50:163
electroencephalography, Alzheimer's disease, 50:163
electroencephalography, temporal lobes, 50:163
temporal lobes, aging, 50:163
temporal lobes, Alzheimer's disease, 50:163
temporal lobes, electroencephalography, 50:163
Myotonic dystrophy
aging, basal ganglia, 50:93
aging, frontal lobes, 50:93
aging, positron emission tomography, 50:93
basal ganglia, aging, 50:93
basal ganglia, frontal lobes, 50:93
basal ganglia, positron emission tomography, 50:93
frontal lobes, aging, 50:93
frontal lobes, basal ganglia, 50:93
frontal lobes, positron emission tomography, 50:93
positron emission tomography, aging, 50:93
positron emission tomography, basal ganglia, 50:93
positron emission tomography, frontal lobes, 50:93
Neurological soft signs
basal ganglia, computed tomography, 50:143
Neurological soft signs continued
basal ganglia, obsessive-compulsive disorder, 50:143
basal ganglia, ventricle-brain ratio, 50:143
computed tomography, basal ganglia, 50:143
computed tomography, obsessive-compulsive disorder, 50:143
computed tomography, ventricle-brain ratio, 50:143
obsessive-compulsive disorder, basal ganglia, 50:143
obsessive-compulsive disorder, computed tomography, 50:143
obsessive-compulsive disorder, ventricle-brain ratio, 50:143
ventricle-brain ratio, basal ganglia, 50:143
ventricle-brain ratio, obsessive-compulsive disorder, 50:143
Nootropics
cognition, electroencephalography, 50:275
cognition, piracetam, 50:275
cognition, topographic analysis, 50:275
electroencephalography, cognition, 50:275
electroencephalography, piracetam, 50:275
electroencephalography, topographic analysis, 50:275
piracetam, cognition, 50:275
piracetam, electroencephalography, 50:275
piracetam, topographic analysis, 50:275
topographic analysis, cognition, 50:275
topographic analysis, electroencephalography, 50:275
topographic analysis, piracetam, 50:275
Obsessive-compulsive disorder
basal ganglia, computed tomography, 50:143
basal ganglia, magnetic resonance imaging, 50:89
basal ganglia, neurological soft signs, 50:143
basal ganglia, ventricle-brain ratio, 50:143
caudate nucleus, magnetic resonance imaging, 50:89
clinical response prediction, electroencephalography, 50:25
clinical response prediction, fluoxetine, 50:25
clinical response prediction, serotonin reuptake inhibitors, 50:25
computed tomography, basal ganglia, 50:143
computed tomography, neurological soft signs, 50:143
computed tomography, ventricle-brain ratio, 50:143
electroencephalography, clinical response prediction, 50:25
electroencephalography, fluoxetine, 50:25

Obsessive-compulsive disorder continued
electroencephalography, serotonin reuptake inhibitors, 50:25
fluoxetine, clinical response prediction, 50:25
fluoxetine, electroencephalography, 50:25
magnetic resonance imaging, basal ganglia, 50:89
magnetic resonance imaging, caudate nucleus, 50:89
neurological soft signs, basal ganglia, 50:143
neurological soft signs, computed tomography, 50:143
neurological soft signs, ventricle-brain ratio, 50:143
serotonin reuptake inhibitors, clinical response prediction, 50:25
serotonin reuptake inhibitors, electroencephalography, 50:25
ventricle-brain ratio, basal ganglia, 50:143
ventricle-brain ratio, neurological soft signs, 50:143
Parietal lobes
catatonia, frontal lobes, 50:203
catatonia, iodoamphetamine, 50:203
catatonia, regional cerebral blood flow, 50:203
catatonia, schizophrenia, 50:203
catatonia, single photon emission computed tomography, 50:203
frontal lobes, catatonia, 50:203
frontal lobes, iodoamphetamine, 50:203
frontal lobes, regional cerebral blood flow, 50:203
frontal lobes, schizophrenia, 50:203
frontal lobes, single photon emission computed tomography, 50:203
iodoamphetamine, catatonia, 50:203
iodoamphetamine, frontal lobes, 50:203
iodoamphetamine, regional cerebral blood flow, 50:203
iodoamphetamine, schizophrenia, 50:203
iodoamphetamine, single photon emission computed tomography, 50:203
regional cerebral blood flow, catatonia, 50:203
regional cerebral blood flow, frontal lobes, 50:203
regional cerebral blood flow, iodoamphetamine, 50:203
regional cerebral blood flow, schizophrenia, 50:203
schizophrenia, catatonia, 50:203
schizophrenia, frontal lobes, 50:203
schizophrenia, iodoamphetamine, 50:203
Parietal lobes continued
schizophrenia, regional cerebral blood flow, 50:203
schizophrenia, single photon emission computed tomography, 50:203
single photon emission computed tomography, catatonia, 50:203
single photon emission computed tomography, frontal lobes, 50:203
single photon emission computed tomography, iodoamphetamine, 50:203
single photon emission computed tomography, schizophrenia, 50:203
Pharmacokinetics
lithium, magnetic resonance spectroscopy, 50:67
magnetic resonance spectroscopy, lithium, 50:67
Phobia
anxiety, positron emission tomography, 50:15
anxiety, regional cerebral blood flow, 50:15
positron emission tomography, anxiety, 50:15
positron emission tomography, regional cerebral blood flow, 50:15
positron emission tomography, snake anxiety, 50:15
regional cerebral blood flow, anxiety, 50:15
regional cerebral blood flow, positron emission tomography, 50:15
snake anxiety, positron emission tomography, 50:15
Piracetam
cognition, electroencephalography, 50:275
cognition, topographic analysis, 50:275
electroencephalography, cognition, 50:275
electroencephalography, topographic analysis, 50:275
topographic analysis, cognition, 50:275
topographic analysis, electroencephalography, 50:275
Positron emission tomography
aging, basal ganglia, 50:93
aging, frontal lobes, 50:93
aging, myotonic dystrophy, 50:93
alcohol dependence, benzodiazepine receptor, 50:1
alcohol dependence, flumazenil, 50:1
alcohol dependence, magnetic resonance imaging, 50:1
anxiety, phobia, 50:15
anxiety, regional cerebral blood flow, 50:15
basal ganglia, aging, 50:93
basal ganglia, dopamine D_2 receptor, 50:217
basal ganglia, frontal lobes, 50:93

Positron emission tomography continued
basal ganglia, methamphetamine psychosis, 50:217
basal ganglia, methylspiperone, 50:217
basal ganglia, myotonic dystrophy, 50:93
basal ganglia, serotonin S_2 receptors, 50:217
benzodiazepine receptor, alcohol dependence, 50:1
benzodiazepine receptor, flumazenil, 50:1
benzodiazepine receptor, magnetic resonance imaging, 50:1
dopamine D_2 receptors, basal ganglia, 50:217
dopamine D_2 receptors, methamphetamine psychosis, 50:217
dopamine D_2 receptors, methylspiperone, 50:217
dopamine D_2 receptors, serotonin S_2 receptors, 50:217
flumazenil, alcohol dependence, 50:1
flumazenil, benzodiazepine receptor, 50:1
flumazenil, magnetic resonance imaging, 50:1
frontal lobes, aging, 50:93
frontal lobes, basal ganglia, 50:93
frontal lobes, myotonic dystrophy, 50:93
magnetic resonance imaging, alcohol dependence, 50:1
magnetic resonance imaging, benzodiazepine receptor, 50:1
magnetic resonance imaging, flumazenil, 50:1
methamphetamine psychosis, basal ganglia, 50:217
methamphetamine psychosis, dopamine D_2 receptors, 50:217
methamphetamine psychosis, methylspiperone, 50:217
methamphetamine psychosis, serotonin S_2 receptors, 50:217
methylspiperone, basal ganglia, 50:217
methylspiperone, dopamine D_2 receptors, 50:217
methylspiperone, methamphetamine psychosis, 50:217
methylspiperone, serotonin S_2 receptors, 50:217
myotonic dystrophy, aging, 50:93
myotonic dystrophy, basal ganglia, 50:93
myotonic dystrophy, frontal lobes, 50:93
phobia, anxiety, 50:15
phobia, regional cerebral blood flow, 50:15
regional cerebral blood flow, anxiety, 50:15
regional cerebral blood flow, phobia, 50:15
serotonin S_2 receptors, basal ganglia, 50:217
serotonin S_2 receptors, dopamine D_2 receptors, 50:217
Positron emission tomography continued
serotonin S_2 receptors, methamphetamine psychosis, 50:217
serotonin S_2 receptors, methylspiperone, 50:217
Pursuit rotor task
motor learning, schizophrenia, 50:33
schizophrenia, motor learning, 50:33
Regional cerebral blood flow
affective disorder, aging, 50:233
affective disorder, frontal lobes, 50:77
affective disorder, single photon emission computed tomography, 50:77, 50:233
aging, affective disorder, 50:233
aging, single photon emission computed tomography, 50:233
aging, unipolar depression, 50:233
anxiety, positron emission tomography, 50:15
catatonia, frontal lobes, 50:203
catatonia, iodoamphetamine, 50:203
catatonia, parietal lobes, 50:203
catatonia, schizophrenia, 50:203
catatonia, single photon emission computed tomography, 50:203
frontal lobes, affective disorder, 50:77
frontal lobes, catatonia, 50:203
frontal lobes, iodoamphetamine, 50:203
frontal lobes, parietal lobes, 50:203
frontal lobes, schizophrenia, 50:203
frontal lobes, single photon emission computed tomography, 50:77, 50:177, 50:203
frontal lobes, task difficulty, 50:177
frontal lobes, unipolar depression, 50:77
frontal lobes, Wisconsin Card Sorting Test, 50:177
iodoamphetamine, catatonia, 50:203
iodoamphetamine, frontal lobes, 50:203
iodoamphetamine, parietal lobes, 50:203
iodoamphetamine, schizophrenia, 50:203
iodoamphetamine, single photon emission computed tomography, 50:203
parietal lobes, catatonia, 50:203
parietal lobes, frontal lobes, 50:203
parietal lobes, iodoamphetamine, 50:203
parietal lobes, schizophrenia, 50:203
parietal lobes, single photon emission computed tomography, 50:203
phobia, positron emission tomography, 50:15
positron emission tomography, anxiety, 50:15
positron emission tomography, phobia, 50:15
schizophrenia, catatonia, 50:203
schizophrenia, frontal lobes, 50:203
schizophrenia, iodoamphetamine, 50:203

Regional cerebral blood flow
schizophrenia, parietal lobes, 50:203
schizophrenia, single photon emission computed tomography, 50:203
single photon emission computed tomography, affective disorder, 50:77, 50:233
single photon emission computed tomography, aging, 50:233
single photon emission computed tomography, catatonia, 50:233
single photon emission computed tomography, frontal lobes, 50:77, 50:177, 50:233
single photon emission computed tomography, iodoamphetamine, 50:233
single photon emission computed tomography, parietal lobes, 50:203
single photon emission computed tomography, schizophrenia, 50:203
single photon emission computed tomography, task difficulty, 50:177
single photon emission computed tomography, unipolar depression, 50:77, 50:233
single photon emission computed tomography, Wisconsin Card Sorting Test, 50:177
task difficulty, frontal lobes, 50:177
task difficulty, single photon emission computed tomography, 50:177
task difficulty, Wisconsin Card Sorting Test, 50:177
unipolar depression, aging, 50:233
unipolar depression, frontal lobes, 50:77
unipolar depression, single photon emission computed tomography, 50:77, 50:233
Wisconsin Card Sorting Test, frontal lobes, 50:177
Wisconsin Card Sorting Test, single photon emission computed tomography, 50:177
Wisconsin Card Sorting Test, task difficulty, 50:177
Schizophrenia
basal ganglia, magnetic resonance imaging, 50:33
basal ganglia, motor learning, 50:33
basal ganglia, tardive dyskinesia, 50:33
catatonia, frontal lobes, 50:203
catatonia, iodoamphetamine, 50:203
catatonia, parietal lobes, 50:203
catatonia, regional cerebral blood flow, 50:203
catatonia, single photon emission computed tomography, 50:203
cavum septum pellucidum, development, 50:193
cavum septum pellucidum, magnetic resonance imaging, 50:193
Schizophrenia continued
development, cavum septum pellucidum, 50:193
development, magnetic resonance imaging, 50:193
frontal lobes, catatonia, 50:203
frontal lobes, iodoamphetamine, 50:203
frontal lobes, parietal lobes, 50:203
frontal lobes, regional cerebral blood flow, 50:203
frontal lobes, single photon emission computed tomography, 50:203
head size, magnetic resonance imaging, 50:121
iodoamphetamine, catatonia, 50:203
iodoamphetamine, frontal lobes, 50:203
iodoamphetamine, parietal lobes, 50:203
iodoamphetamine, regional cerebral blood flow, 50:203
iodoamphetamine, single photon emission computed tomography, 50:203
magnetic resonance imaging, basal ganglia, 50:33
magnetic resonance imaging, cavum septum pellucidum, 50:193
magnetic resonance imaging, development, 50:193
magnetic resonance imaging, head size, 50:121
magnetic resonance imaging, memory, 50:45
magnetic resonance imaging, motor learning, 50:33
magnetic resonance imaging, tardive dyskinesia, 50:33
magnetic resonance imaging, temporal lobe area, 50:45
memory, magnetic resonance imaging, 50:45
memory, temporal lobe area, 50:45
motor learning, basal ganglia, 50:33
motor learning, magnetic resonance imaging, 50:33
motor learning, tardive dyskinesia, 50:33
parietal lobes, catatonia, 50:203
parietal lobes, frontal lobes, 50:203
parietal lobes, iodoamphetamine, 50:203
parietal lobes, regional cerebral blood flow, 50:203
parietal lobes, single photon emission computed tomography, 50:203
regional cerebral blood flow, catatonia, 50:203
regional cerebral blood flow, frontal lobes, 50:203
regional cerebral blood flow, iodoamphetamine, 50:203

Schizophrenia continued
regional cerebral blood flow, parietal lobes, 50:203
single photon emission computed tomography, catatonia, 50:203
single photon emission computed tomography, frontal lobes, 50:203
single photon emission computed tomography, iodoamphetamine, 50:203
single photon emission computed tomography, parietal lobes, 50:203
tardive dyskinesia, basal ganglia, 50:33
tardive dyskinesia, magnetic resonance imaging, 50:33
tardive dyskinesia, motor learning, 50:33
temporal lobe area, magnetic resonance imaging, 50:45
temporal lobe area, memory, 50:45
Serotonin
basal ganglia, dopamine D_2 receptors, 50:217
basal ganglia, methamphetamine psychosis, 50:217
basal ganglia, methylspiperone, 50:217
basal ganglia, positron emission tomography, 50:217
clinical response prediction, electroencephalography, 50:25
clinical response prediction, obsessive-compulsive disorder, 50:25
dopamine D_2 receptors, basal ganglia, 50:217
dopamine D_2 receptors, methamphetamine psychosis, 50:217
dopamine D_2 receptors, methylspiperone, 50:217
dopamine D_2 receptors, positron emission tomography, 50:217
electroencephalography, clinical response prediction, 50:25
electroencephalography, obsessive-compulsive disorder, 50:25
methamphetamine psychosis, basal ganglia, 50:217
methamphetamine psychosis, dopamine D_2 receptors, 50:217
methamphetamine psychosis, methylspiperone, 50:217
methamphetamine psychosis, positron emission tomography, 50:217
methylspiperone, basal ganglia, 50:217
methylspiperone, dopamine D_2 receptors, 50:217
methylspiperone, methamphetamine psychosis, 50:217
methylspiperone, positron emission tomography, 50:217
Serotonin continued
obsessive-compulsive disorder, clinical response prediction, 50:25
obsessive-compulsive disorder, electroencephalography, 50:25
positron emission tomography, basal ganglia, 50:217
positron emission tomography, dopamine D_2 receptors, 50:217
positron emission tomography, methamphetamine psychosis, 50:217
positron emission tomography, methylspiperone, 50:217
Single photon emission computed tomography
affective disorder, aging, 50:233
affective disorder, frontal lobes, 50:77
affective disorder, regional cerebral blood flow, 50:77, 50:233
aging, affective disorder, 50:233
aging, regional cerebral blood flow, 50:233
aging, unipolar depression, 50:233
catatonia, frontal lobes, 50:203
catatonia, iodoamphetamine, 50:203
catatonia, parietal lobes, 50:203
catatonia, regional cerebral blood flow, 50:203
catatonia, schizophrenia, 50:203
frontal lobes, affective disorder, 50:77
frontal lobes, catatonia, 50:203
frontal lobes, iodoamphetamine, 50:203
frontal lobes, parietal lobes, 50:203
frontal lobes, regional cerebral blood flow, 50:77, 50:177, 50:203
frontal lobes, schizophrenia, 50:203
frontal lobes, task difficulty, 50:177
frontal lobes, unipolar depression, 50:77
frontal lobes, Wisconsin Card Sorting Test, 50:177
image registration, magnetic resonance imaging, 50:57
image registration, region of interest, 50:57
iodoamphetamine, catatonia, 50:203
iodoamphetamine, frontal lobes, 50:203
iodoamphetamine, parietal lobes, 50:203
iodoamphetamine, regional cerebral blood flow, 50:203
iodoamphetamine, schizophrenia, 50:203
magnetic resonance imaging, image registration, 50:57
magnetic resonance imaging, region of interest, 50:57
parietal lobes, catatonia, 50:203
parietal lobes, frontal lobes, 50:203
parietal lobes, iodoamphetamine, 50:203

Single photon emission computed tomography continued
parietal lobes, regional cerebral blood flow, 50:203
parietal lobes, schizophrenia, 50:203
region of interest, image registration, 50:57
region of interest, magnetic resonance imaging, 50:57
regional cerebral blood flow, affective disorder, 50:77, 50:233
regional cerebral blood flow, aging, 50:233
regional cerebral blood flow, catatonia, 50:203
regional cerebral blood flow, frontal lobes, 50:77, 50:177, 50:203
regional cerebral blood flow, iodoamphetamine, 50:203
regional cerebral blood flow, parietal lobes, 50:203
regional cerebral blood flow, schizophrenia, 50:203
regional cerebral blood flow, task difficulty, 50:177
regional cerebral blood flow, unipolar depression, 50:77, 50:233
regional cerebral blood flow, Wisconsin Card Sorting Test, 50:177
schizophrenia, catatonia, 50:203
schizophrenia, frontal lobes, 50:203
schizophrenia, iodoamphetamine, 50:203
schizophrenia, parietal lobes, 50:203
schizophrenia, regional cerebral blood flow, 50:203
task difficulty, frontal lobes, 50:177
task difficulty, regional cerebral blood flow, 50:177
task difficulty, Wisconsin Card Sorting Test, 50:177
unipolar depression, affective disorder, 50:77, 50:233
unipolar depression, aging, 50:233
unipolar depression, frontal lobes, 50:77
unipolar depression, regional cerebral blood flow, 50:77, 50:233
Wisconsin Card Sorting Test, frontal lobes, 50:177
Wisconsin Card Sorting Test, regional cerebral blood flow, 50:177
Wisconsin Card Sorting Test, task difficulty, 50:177
Tardive dyskinesia
basal ganglia, magnetic resonance imaging, 50:33
basal ganglia, motor learning, 50:33
basal ganglia, schizophrenia, 50:33
Tardive dyskinesia continued
magnetic resonance imaging, basal ganglia, 50:33
magnetic resonance imaging, motor learning, 50:33
magnetic resonance imaging, schizophrenia, 50:33
motor learning, basal ganglia, 50:33
motor learning, magnetic resonance imaging, 50:33
motor learning, schizophrenia, 50:33
schizophrenia, basal ganglia, 50:33
schizophrenia, magnetic resonance imaging, 50:33
schizophrenia, motor learning, 50:33
Temporal lobes
aging, Alzheimer's disease, 50:163
aging, electroencephalography, 50:163
aging, motor performance, 50:163
Alzheimer's disease, aging, 50:163
Alzheimer's disease, electroencephalography, 50:163
Alzheimer's disease, motor performance, 50:163
electroencephalography, aging, 50:163
electroencephalography, Alzheimer's disease, 50:163
electroencephalography, motor performance, 50:163
magnetic resonance imaging, memory, 50:45
magnetic resonance imaging, schizophrenia, 50:45
memory, magnetic resonance imaging, 50:45
memory, schizophrenia, 50:45
motor performance, aging, 50:163
motor performance, Alzheimer's disease, 50:163
motor performance, electroencephalography, 50:163
schizophrenia, magnetic resonance imaging, 50:45
schizophrenia, memory, 50:45
Ventricle-brain ratio
aging, alcohol dependence, 50:257
aging, cerebrospinal fluid volume, 50:257
aging, computed tomography, 50:257
aging, magnetic resonance imaging, 50:257
alcohol dependence, aging, 50:257
alcohol dependence, cerebrospinal fluid volume, 50:257
alcohol dependence, computed tomography, 50:257
alcohol dependence, magnetic resonance imaging, 50:1, 50:257
basal ganglia, computed tomography, 50:143

Ventricle-brain ratio continued
basal ganglia, neurological soft signs, 50:143
basal ganglia, obsessive-compulsive disorder, 50:143
cerebrospinal fluid volume, aging, 50:257
cerebrospinal fluid volume, alcohol dependence, 50:257
cerebrospinal fluid volume, computed tomography, 50:257
cerebrospinal fluid volume, magnetic resonance imaging, 50:257
computed tomography, aging, 50:257
computed tomography, alcohol dependence, 50:257
computed tomography, basal ganglia, 50:143
computed tomography, cerebrospinal fluid volume, 50:257
computed tomography, head size, 50:121
computed tomography, magnetic resonance imaging, 50:121, 50:257
computed tomography, neurological soft signs, 50:143
computed tomography, obsessive-compulsive disorder, 50:143
head size, computed tomography, 50:121
head size, magnetic resonance imaging, 50:121
magnetic resonance imaging, aging, 50:257
magnetic resonance imaging, alcohol dependence, 50:1, 50:257
magnetic resonance imaging, cerebrospinal fluid volume, 50:257
magnetic resonance imaging, computed tomography, 50:121, 50:257
magnetic resonance imaging, head size, 50:121
magnetic resonance imaging, schizophrenia, 50:45
magnetic resonance imaging, Wechsler Memory Scale, 50:45
Ventricle-brain ratio continued
neurological soft signs, basal ganglia, 50:143
neurological soft signs, computed tomography, 50:143
neurological soft signs, obsessive-compulsive disorder, 50:143
obsessive-compulsive disorder, basal ganglia, 50:143
obsessive-compulsive disorder, computed tomography, 50:143
obsessive-compulsive disorder, neurological soft signs, 50:143
schizophrenia, magnetic resonance imaging, 50:45
schizophrenia, Wechsler Memory Scale, 50:45
Wechsler Memory Scale, magnetic resonance imaging, 50:45
Wechsler Memory Scale, schizophrenia, 50:45
Wisconsin Card Sorting Test
frontal lobes, regional cerebral blood flow, 50:177
frontal lobes, single photon emission computed tomography, 50:177
frontal lobes, task difficulty, 50:177
regional cerebral blood flow, frontal lobes, 50:177
regional cerebral blood flow, task difficulty, 50:177
single photon emission computed tomography, frontal lobes, 50:177
single photon emission computed tomography, task difficulty, 50:177
task difficulty, frontal lobes, 50:177
task difficulty, regional cerebral blood flow, 50:177
task difficulty, single photon emission computed tomography, 50:177